Repositioning of the global epicentre of non-optimal cholesterol

Published: Nature
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Published: Nature
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities1,2. This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity3-6

Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19ยท1 million participants

Published: The Lancet
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Raised blood pressure is an important risk factor for cardiovascular diseases and chronic kidney disease. We estimated worldwide trends in mean systolic and mean diastolic blood pressure, and the prevalence of, and number of people with, raised blood pressure, defined as systolic blood pressure of 140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or higher.

A pilot study of QT interval analysis in overweight and obese youth

Published: Applied Nursing Research
Date:
Authors: Shirleatha Lee 1 , Patricia Ann Cowan, Pedro Velasquez-Mieyer
Abstract:
This descriptive pilot study examined if manual corrected QT (QTc) interval measures obtained from a standard 12-lead electrocardiogram (ECG) correlated with automated 24-hour ambulatory Holter QTc measures in 30 overweight and obese youth aged 12-17 years.

Metabolic syndrome: from global epidemiology to individualized medicine

Published: Clinical Pharmacology & Therapeutics
Date:
Authors: J A Batsis 1 , R E Nieto-Martinez, F Lopez-Jimenez
Abstract:
The metabolic syndrome (MetS) encompasses a constellation of metabolic abnormalities that are thought to place patients at higher risk for the development of diabetes and cardiovascular (CV) disease.

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

Published: International Journal of Obesity
Date:
Authors: R H Lustig 1 , F Greenway, P Velasquez-Mieyer, D Heimburger, D Schumacher, D Smith, W Smith, N Soler, G Warsi, W Berg, J Maloney, J Benedetto, W Zhu, J Hohneker
Abstract:
To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.